TS-075255 — Problem The limited regenerative capacity of adult CNS neurons upon transection results in chronic neurological disability. There is an urgent need to develop novel therapies that facilitate CNS axon regeneration and ultimately restore lost neurological functions. Solution Applications Advan…

TS-075243 — Problem Central nervous system (CNS) injury can result in permanent neurological disability and vision loss. There is a dire need to develop novel therapies that overcome barriers to repair within the CNS and promote neuron survival and axon regeneration. Solution Applicat…

TS-075191 — PROBLEM Cancer immunotherapies (e.g. ICB, CAR-T cells, and conventional bispecific T cell engagers) have transformed treatment of hematological and solid malignancies; however, their impact is limited by several factors including insufficient durability of therapeutic activity, tumor heterogeneity,…

TS-075167 — PROBLEM CAR T-cell therapy against CD19 has become the standard of care for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), the most common kind of lymphoma. Recent studies have identified clinical risk factors for prediction of CAR T therapy failure; however, these risk factors are inconsis…

TS-075163 — THE PROBLEM High-grade gliomas, including glioblastoma multiforme (GBM), are the most common primary central nervous system tumors with a high recurrence rate and extremely poor overall survival with a 5-year survival rate of approximately 5%. Despite success of CAR-T therapy in treating blood canc…

TS-075162 — THE PROBLEM Despite advances in classical Hodgkin’s Lymphoma (cHL) treatment, significant challenges persist with up to 40% of patients relapsing after first-line therapy and 50% after autologous stem cell transplant (aSCT). Current therapies like brentuximab vedotin and checkpoint inhibitors…

TS-075161 — Problem Acute and chronic pulmonary inflammation conditions, such as acute respiratory distress syndrome (ARDS), acute lung injury (ALI) and asthma, remain a significant healthcare challenge with high mortality rates, long-term morbidity and a substantial economic burden due to prolonged hospital s…

TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health

TS-065435 — The Need: The treatment landscape for multiple myeloma (MM) demands novel, targeted solutions to improve patient outcomes. Existing therapies often fall short in addressing the complex challenges posed by MM, necessitating a more precise and effective approach. The Technology: Our technology introd…

TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.